MERK Stock Overview
Engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
PT Merck Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp3,950.00 |
| 52 Week High | Rp5,100.00 |
| 52 Week Low | Rp3,830.00 |
| Beta | 0.63 |
| 11 Month Change | 0.77% |
| 3 Month Change | -1.25% |
| 1 Year Change | -17.02% |
| 33 Year Change | 18.98% |
| 5 Year Change | 4.50% |
| Change since IPO | 1,323.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| MERK | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | -2.7% | 0.4% | -1.2% |
| 1Y | -17.0% | -18.1% | 9.4% |
Return vs Industry: MERK exceeded the ID Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: MERK underperformed the ID Market which returned 9.4% over the past year.
Price Volatility
| MERK volatility | |
|---|---|
| MERK Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in ID Market | 12.8% |
| 10% least volatile stocks in ID Market | 2.9% |
Stable Share Price: MERK has not had significant price volatility in the past 3 months.
Volatility Over Time: MERK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | 381 | Evie Yulin | www.merckgroup.com/id-id |
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through three segments: Biopharma, Consumer Health, and Others. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines.
PT Merck Tbk Fundamentals Summary
| MERK fundamental statistics | |
|---|---|
| Market cap | Rp1.77t |
| Earnings (TTM) | Rp155.58b |
| Revenue (TTM) | Rp949.80b |
11.4x
P/E Ratio1.9x
P/S RatioIs MERK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MERK income statement (TTM) | |
|---|---|
| Revenue | Rp949.80b |
| Cost of Revenue | Rp577.95b |
| Gross Profit | Rp371.85b |
| Other Expenses | Rp216.26b |
| Earnings | Rp155.58b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 347.29 |
| Gross Margin | 39.15% |
| Net Profit Margin | 16.38% |
| Debt/Equity Ratio | 0% |
How did MERK perform over the long term?
See historical performance and comparison